Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma)

NCT00368121 is registered in ClinicalTrials.gov with Prof. Dr. Andreas Engert as lead sponsor.

NCT NCT00368121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00368121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma)
Lead sponsor
Prof. Dr. Andreas Engert
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2006
Completion date
June 30, 2012
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma